FCN-011

FCN-011 is a novel, orally administered small molecule that acts as a pan-tropomyosin receptor kinase (pan-TRK) inhibitor. It targets the protein tyrosine kinases encoded by the NTRK gene family, which are implicated in oncogenic fusions driving various solid tumors. By inhibiting TRK proteins, FCN-011 disrupts downstream signaling pathways involved in tumor cell growth and survival. The drug was developed by Chongqing Fochon Pharmaceutical (Fochon Pharmaceuticals), a subsidiary of Shanghai Fosun Pharmaceutical Group. Its primary indication is for advanced solid tumors, particularly those harboring NTRK fusions. As of 2024, it has reached Phase 2 clinical trials for NTRK fusion-positive solid tumors and Phase 1 for advanced malignant solid neoplasms[1][2][3][5].